This is an evidence-based guideline on the management of diffuse large B-cell lymphoma (DLBL). Guidance is given on staging the disease, and on the use of various conventional and molecular genetic methods to assess prognosis at the time of diagnosis. There are separate sections dealing with the approach to the treatment of early and advanced stage DLBL, and guidance is also given on the management of patients with relapsed/refractory disease who are eligible for tranplantation, and on treatment approaches in elderly/unfit patients.
Declaration of Interests
The BSH paid the expenses incurred during the writing of this guidance. None of the authors had conflicts of interest to declare. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.